Zum Inhalt springen

For information & educational purposes only — not medical advice, no dosing or usage recommendation.

Beginner view — everything explained simply.

The detailed substance texts are currently available in German only. The interface and navigation are translated; the specialist content will follow in reviewed quality.

Always up to date

New & updated

What was recently added to PeptidLotse — new guides, research compounds and dated research updates, gathered chronologically. See at a glance what has changed since your last visit.

  1. Peptide profile

    9 new peptide profiles + orforglipron

    New substance profiles for the most prominent incretin and amylin candidates of 2025/26 — including amycretin, MariTide, VK2735, petrelintide, enlicitide (Lipfendra) and palopegteriparatide (Yorvipath). Orforglipron (a non-peptide oral GLP-1) joins the research compounds. Every claim checked against primary sources, without dosing or usage information.

  2. Research compound

    Orforglipron

    Der erste orale GLP-1-Wirkstoff aus einem kleinen Molekül – kein Peptid, keine Spritze, keine Einnahme-Restriktionen.

  3. New feature

    New: the “What’s new” overview

    This page now brings every addition to the app together in one place — new guides, research compounds and dated research updates. Returning visitors get a subtle heads-up when something is new.

  4. Guide

    Reading a Certificate of Analysis (CoA) and HPLC purity correctly

    What a Certificate of Analysis (CoA) must contain, what an HPLC purity of "99 %" really says - and what it does not -, why purity is not the same as identity, and how to recognize useless or forged gray-market certificates. Quality and risk awareness, without sourcing or usage guidance.

  5. Guide

    Understanding half-life: t½, steady state, and why peptides act over such different timescales

    What the half-life (t½) really means - the four-to-five-half-lives rule of thumb, steady state and accumulation with repeated administration, the difference between plasma and effect half-life, and why peptides range from minutes to days. Explained soberly, without dosages.

  6. Research compound

    CMS121

    Salk research molecule (Maher/Schubert) derived from the plant compound fisetin – studied as a "geroneuroprotector" against brain aging and Alzheimer's.

  7. Research compound

    CNB-001

    Synthetic curcumin derivative from the Salk Institute – neuroprotective precursor of J-147, studied exclusively preclinically.

  8. Research compound

    Dihexa

    A synthetic angiotensin IV derivative whose cognition-enhancing effect rests on a now-retracted research basis.

  9. Research compound

    J-147

    Experimental neuroprotective drug candidate from the Salk Institute that targets the energy metabolism of the nerve cell rather than amyloid.

  10. New feature

    New section: research compounds

    Dedicated profiles for non-peptide research molecules (small molecules) — launched with J-147 and expanding. As everywhere: backed by primary sources, without dosing or usage information.

  11. Research update

    Peptide Research 2024–2026: What the Studies Actually Show

    A sober overview of the latest peptide research: where the approved incretin class convinces with hard Phase 3 data, where even Semaglutide fails – and why "wellness" peptides such as BPC-157 or Epitalon still stand without any controlled human trials.

Dates indicate publication or update on PeptidLotse — not the date of the underlying studies.